Oxybutynin Chloride Tablet, Extended Release
Product Images NDC 0904-6570

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Oxybutynin Chloride (NDC 0904-6570). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

C7ad16c7 Ae48 4ab1 Bebb 19897aa80159 00

Oxybutynin Chloride extended-release tablets 5 mg by Major Pharmaceuticals. The label shows the product as a unit dose of 100 tablets, oral route. It includes dosage information, storage instructions advising controlled room temperature conditions, and indicates the product is Rx only. Distributed by Amneal Pharmaceuticals LLC and Major Pharmaceuticals.*

FDA Label Image

Structural Formula (Oxybutynin Chloride Extended Release Tablets Usp 1)

Chemical structure of oxybutynin chloride illustrating its molecular components and bonds, including aromatic rings, ester, alkyne, and amine groups.*

FDA Label Image

Figure 1 (Oxybutynin Chloride Extended Release Tablets Usp 2)

A line graph showing mean plasma R-oxybutynin concentration (ng/mL) over 24 hours. It compares two dosing regimens of oxybutynin chloride: 10 mg once daily (QD) represented by a solid line with circles, and 5 mg three times daily (TID) represented by a dashed line with circles. The y-axis indicates concentration from 0 to 5 ng/mL and the x-axis shows time in hours from 0 to 24.*

FDA Label Image

Figure 2 (Oxybutynin Chloride Extended Release Tablets Usp 3)

A line graph showing mean R-Oxybutynin plasma concentration (ng/mL) over time (hours) up to 24 hours. The graph includes data points with error bars indicating variability at multiple time intervals. Plasma concentration fluctuates around 0.5 to 0.7 ng/mL, peaking near 5 hours and then gradually returning toward the initial concentration by 24 hours.*

FDA Label Image

Study 1 (Oxybutynin Chloride Extended Release Tablets Usp 4)

A horizontal error bar chart comparing Oxybutynin Chloride and Placebo. The chart shows horizontal lines with markers and bars indicating variability, positioned on a scale from -40 to 40 with a midpoint at 0. Oxybutynin Chloride's bar extends from approximately -30 to -5, while Placebo's bar extends from near -18 to about 1.*

FDA Label Image

Study 2 (Oxybutynin Chloride Extended Release Tablets Usp 5)

A horizontal error bar chart comparing two items labeled 'Oxybutynin Chloride' and 'oxybutynin' centered near the -20 mark on the x-axis, with error bars extending approximately from -40 to 0. The x-axis ranges from -40 to 40, and vertical reference lines are at x=0 and x=20.*

FDA Label Image

Study 3 (Oxybutynin Chloride Extended Release Tablets Usp 6)

A horizontal error bar chart comparing two measurements labeled 'Oxybutynin Chloride' and 'oxybutynin' along a numerical scale ranging from -40 to 40. Both measurements have data points placed near the center of the scale with horizontal bars extending slightly to the left, indicating a range with values below zero.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.